Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell-B) filed its Monthly Return for Equity Issuers for the period ended 30 June 2026, confirming stable capital structure and full compliance with Hong Kong Stock Exchange public-float rules.
Total authorised share capital remained unchanged at 446.73 million shares with a par value of RMB 1 each, comprising: • 47.13 million H shares listed in Hong Kong • 399.60 million A shares listed on the Shanghai Stock Exchange
Issued share capital showed no movement during the month: • H-share count held at 47.13 million, with zero treasury shares. The company affirmed that the public float exceeds the 5 % minimum threshold required for PRC issuers with dual listings. • A-share count stayed at 398.41 million issued shares, with 1.19 million shares held in treasury; total A shares outstanding remained 399.60 million.
The company reported no new share options, warrants, convertible instruments, or other equity-linked agreements during the period.
Mabwell’s board and joint company secretary Wang Hefei confirmed that all applicable listing rules, regulatory requirements, and corporate authorisations were satisfied for the reporting month.
Comments